Clinical Trials Browser

NETWORK × Ovarian Neoplasms × Dasatinib × Clear all

NCT00671788 2016-04-15

A Phase II Evaluation of Dasatinib (Sprycel®, NSC #732517) in the Treatment of Persistent or Recurrent Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Carcinoma

Phase 2 Completed

35 enrolled 8 charts

Fallopian Tube Neoplasms, Ovarian Neoplasms